Sign in to view content

Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model

Andrew A. Moshfeghi, MD, MBA, FASRS

Video
Published 2021

Related

High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
On Demand Cases, Courses, and Papers
2019
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more